Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3VIN): A multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology

Volumn 15, Issue 12, 2014, Pages 1361-1368

  Tristram, Amanda ^a   Hurt, Christopher N ^a   Madden, Tracie ^a   Powell, Ned ^a   Man, Stephen ^a   Hibbitts, Sam ^a   Dutton, Peter ^a   Jones, Sadie ^a   Nordin, Andrew J ^c   Naik, Raj ^d   Fiander, Alison ^a   Griffiths, Gareth ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOSINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTICENTER STUDY; MYALGIA; NEUROLOGIC DISEASE; OPEN STUDY; PAIN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRECANCER; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; TREATMENT RESPONSE; ULCER; UNITED KINGDOM; VULVA DISEASE; VULVAL INTRAEPITHELIAL NEOPLASIA; VULVODYNIA; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CANCER GRADING; CARCINOMA IN SITU; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; VULVAR NEOPLASMS;

ADULT; AMINOQUINOLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA IN SITU; CYTOSINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; ORGANOPHOSPHONATES; VULVAR NEOPLASMS;

EID: 84908620796     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70456-5     Document Type: Article

References (25)

1. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006, 107:1018-1022.
2. Baandrup L, Varbo A, Munk C, Johansen C, Frisch M, Kjaer SK In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978-2007: a nationwide population-based study. Gynecol Oncol 2011, 122:45-49.
3. de Sanjose S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013, 49:3450-3461.
4. McCluggage WG Recent developments in vulvovaginal pathology. Histopathology 2009, 54:156-173.
5. Shylasree TS, Karanjgaokar V, Tristram A, Wilkes AR, MacLean AB, Flander AN Contribution of demographic, psychological and disease-related factors to quality of life in women with high-grade vulval intraepithelial neoplasia. Gynecol Oncol 2008, 110:185-189.
6. van Seters M, van Beurden M, de Craen AJ Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005, 97:645-651.
7. Likes WM, Stegbauer C, Tillmanns T, Pruett J Pilot study of sexual function and quality of life after excision for vulvar intraepithelial neoplasia. J Reprod Med 2007, 52:23-27.
8. Fehr MK, Baumann M, Mueller M, et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. J Gynecol Oncol 2013, 24:236-241.
9. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 2000, 60:205-209.
10. Tristram A, Fiander A Clinical responses to cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecol Oncol 2005, 99:652-655.
11. Davis G, Wentworth J, Richard J Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia: a report of four cases. J Reprod Med 2000, 45:619-623.
12. Jayne CJ, Kaufman RH Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod. J Reprod Med 2002, 47:395-398.
13. Todd RW, Etherington LJ, Luesley DM The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol 2002, 85:67-70.
14. van Seters M, Fons G, van Beurden M Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3: results of a pilot study. J Reprod Med 2002, 47:701-705.
15. Marchitelli C, Secco G, Perrotta M, Lugones L, Pesce R, Testa R Treatment of bowenoid and basaloid vulvar intraepithelial neoplasia 2/3 with irniquimod 5% cream. J Reprod Med 2004, 49:876-882.
16. Wendling J, Saiag P, Berville-Levy S, Bourgault-Villada I, Clerici T, Moyal-Barracco M Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases. Arch Dermatol 2004, 140:1220-1224.
17. Collins SI, Constandinou-Williams C, Wen K, et al. Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study. Cancer Res 2009, 69:3828-3832.
18. Lockhart J, Gray NM, Cruickshank ME The development and evaluation of a questionnaire to assess the impact of vulval intraepithelial neoplasia: a questionnaire study. BJOG 2013, 120:1133-1143.
19. Pepas L, Kaushik S, Bryant A, Nordin A, Dickinson HO Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev 2011, 4. CD007924.
20. Sterling JC, Smith NA, Loo WJ, et al. Randomized, double blind, placebo controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. J Eur Acad Dermatol Venereol 2005, 19(suppl s2):1-58. (abstr FC06.1).
21. Mathiesen O, Buus SK, Cramers M Topical irniquimod can reverse vulvar intraepithelial neoplasia: a randornised, double-blinded study. Gynecol Oncol 2007, 107:219-222.
22. van Seters M, van Beurden M, ten Kate FJW, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008, 358:1465-1473.
23. Westermann C, Fischer A, Clad A Treatment of vulvar intraepithelial neoplasia with topical 5% imiquimod cream. Int J Gynecol Obstet 2013, 120:266-270.
24. Frega A, Sesti F, Sopracordevole F, et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five-year follow-up. Eur Rev Med Pharmacol Sci 2013, 17:936-940.
25. Stier EA, Goldstone SE, Einstein MH, et al. Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS 2013, 27:545-551.